Shopping Cart 0
Cart Subtotal
USD 0

Generics in Australia

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 350

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 700

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 1050
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Generics in Australia industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Findings

Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Australia

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Australia

Leading company profiles reveal details of key generics market players' global operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the Australia generics market with five year forecasts by both value and volume

Synopsis

Essential resource for top-line data and analysis covering the Australia generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Reasons to Buy

What was the size of the Australia generics market by value in 2016?

What will be the size of the Australia generics market in 2021?

What factors are affecting the strength of competition in the Australia generics market?

How has the market performed over the last five years?

How large is Australia's generics market in relation to its regional counterparts?

Key Highlights

For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.

The Australian generics market is forecast to generate total revenues of $1.2bn in 2016, representing a compound annual rate of change (CARC) of -0.5% between 2012 and 2016.

Market consumption volume is forecast to increase with a CAGR of 3.2% between 2012 and 2016, to reach a total of 51.4% of total pharma volume in 2016.

Current pricing policy means that many companies are operating below cost in this market, leading to overall decline in the historic period.

READ MORE

Table Of Content

Scope

Executive Summary

Market value

Market value forecast

Market volume

Market volume forecast

Geography segmentation

Market rivalry

Market Overview

Market definition

Market analysis

Market Data

Market value

Market volume

Market Segmentation

Geography segmentation

Market Outlook

Market value forecast

Market volume forecast

Five Forces Analysis

Summary

Buyer power

Supplier power

New entrants

Threat of substitutes

Degree of rivalry

Leading Companies

Aspen Pharmacare Holdings Ltd

Mylan Inc.

Teva Pharmaceutical Industries Limited

Macroeconomic Indicators

Country data

Methodology

Appendix

About MarketLine


List Of Figure

Figure 1: Australia generics market value: $ billion, 2012-16(e)

Figure 2: Australia generics market volume: % of total pharma volume, 2012-16(e)

Figure 3: Australia generics market geography segmentation: % share, by value, 2016(e)

Figure 4: Australia generics market value forecast: $ billion, 2016-21

Figure 5: Australia generics market volume forecast: % of total pharma volume, 2016-21

Figure 6: Forces driving competition in the generics market in Australia, 2016

Figure 7: Drivers of buyer power in the generics market in Australia, 2016

Figure 8: Drivers of supplier power in the generics market in Australia, 2016

Figure 9: Factors influencing the likelihood of new entrants in the generics market in Australia, 2016

Figure 10: Factors influencing the threat of substitutes in the generics market in Australia, 2016

Figure 11: Drivers of degree of rivalry in the generics market in Australia, 2016

Figure 12: Aspen Pharmacare Holdings Ltd: revenues & profitability

Figure 13: Aspen Pharmacare Holdings Ltd: assets & liabilities

Figure 14: Mylan Inc.: revenues & profitability

Figure 15: Mylan Inc.: assets & liabilities

Figure 16: Teva Pharmaceutical Industries Limited: revenues & profitability

Figure 17: Teva Pharmaceutical Industries Limited: assets & liabilities


List Of Table

Table 1: Australia generics market value: $ billion, 2012-16(e)

Table 2: Australia generics market volume: % of total pharma volume, 2012-16(e)

Table 3: Australia generics market geography segmentation: $ billion, 2016(e)

Table 4: Australia generics market value forecast: $ billion, 2016-21

Table 5: Australia generics market volume forecast: % of total pharma volume, 2016-21

Table 6: Aspen Pharmacare Holdings Ltd: key facts

Table 7: Aspen Pharmacare Holdings Ltd: key financials ($)

Table 8: Aspen Pharmacare Holdings Ltd: key financials (ZAR)

Table 9: Aspen Pharmacare Holdings Ltd: key financial ratios

Table 10: Mylan Inc.: key facts

Table 11: Mylan Inc.: key financials ($)

Table 12: Mylan Inc.: key financial ratios

Table 13: Teva Pharmaceutical Industries Limited: key facts

Table 14: Teva Pharmaceutical Industries Limited: key financials ($)

Table 15: Teva Pharmaceutical Industries Limited: key financial ratios

Table 16: Australia size of population (million), 2012-16

Table 17: Australia gdp (constant 2005 prices, $ billion), 2012-16

Table 18: Australia gdp (current prices, $ billion), 2012-16

Table 19: Australia inflation, 2012-16

Table 20: Australia consumer price index (absolute), 2012-16

Table 21: Australia exchange rate, 2012-16

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Generics, MarketLine, Australia


Companies

Aspen Pharmacare Holdings Ltd, Mylan Inc., Teva Pharmaceutical Industries Limited